Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
19 June 2024 - 8:22AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
biotechnology company developing first-in-classi targeted and
immune-mediated therapeutics to fight cancer, today announced the
company plans to report new data from the global randomized Phase
1b/2 combination study of amezalpat (TPST-1120) with atezolizumab
and bevacizumab in first-line treatment of hepatocellular carcinoma
(HCC) in a premarket press release followed by a webcasted
conference call with associated slide presentation on Thursday,
June 20, 2024 at 8:30 a.m. ET.
To join the conference call via phone and
participate in the live Q&A session, please pre-register online
here to receive a telephone number and unique passcode required to
enter the call. The live webcast and audio archive of the
presentation may be accessed on the investor section of the Tempest
website at https://ir.tempesttx.com/. The webcast will be
available for replay for 30 days.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
biotechnology company advancing a diverse portfolio of small
molecule product candidates containing tumor-targeted and/or
immune-mediated mechanisms with the potential to treat a wide range
of tumors. The company’s novel programs range from early research
to later-stage investigation in a randomized global study in
first-line cancer patients. Tempest is headquartered in Brisbane,
California. More information about Tempest can be found on the
company’s website at www.tempesttx.com.
Investor & Media Contacts
Sylvia Wheeler Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From May 2024 to Jun 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jun 2023 to Jun 2024